Opdivo+Yervoy first-line treatment of advanced renal cell carcinoma shows 30-month long-term survival benefit
BMS announced the latest results of the Phase III CheckMate-214 study on February 11. Opdivo (nivolumab) combined with low-dose Yervoy (ipilimumab) significantly improved OS in the 30-month median follow-up period compared with the sunitinib group for patients with untreated advanced or metastatic renal cells. And at 30 months, Opdivo combined with low-dose Yervoy had an improved ORR in the mid-high-risk population compared to the previous 17.5-month analysis. CheckMate-214 is a randomized, open phase III study evaluating the efficacy of nivolumab in combination with Ipilimumab versus sunitinib in patients with advanced advanced or metastatic renal cell carcinoma (RCC). Patients in the combination group received Nivolumab 3 mg/kg in combination with Ipilimumab 1 mg/kg once every 3 weeks, followed by 4 cycles of sequential Nivolumab 3 mg/kg, once every 2 weeks for single-agent Opdivo; control group received sultanate Nie 50mg, once a day, for 4 weeks of continuous medication, rest for...